Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Seraprevir in Combination With Sofosbuvir in Patients With Chronic Genotype 1 Hepatitis C Virus Infection.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- BeiJing YouAn Hospital ,Capital Medical University
-
Beijing, Beijing, China
- Beijing Ditan Hospital,Capital Medical University
-
Beijing, Beijing, China
- Beijing Friendship Hospital,Capital Medical University
-
-
Chongqing
-
Chongqing, Chongqing, China
- Chongqing Public Health Medical Center
-
Chongqing, Chongqing, China
- Chongqing Sanxia Center Hospital
-
-
Guangxi Zhuang Autonomous Region
-
Liuzhou, Guangxi Zhuang Autonomous Region, China
- Liuzhou General Hospital
-
-
Guizhou
-
Zunyi, Guizhou, China
- Affiliated Hospital of Zunyi Medical University
-
-
Hebei
-
Shijiazhuang, Hebei, China
- The First Hospital of Hebei Medical University
-
-
Henan
-
Zhengzhou, Henan, China
- The Sixth People's Hospital of Zhengzhou
-
-
Hubei
-
Wuhan, Hubei, China
- Tongji hospital affiliated to tongji medical college huazhong university of science and technology
-
Wuhan, Hubei, China
- Wuhan Medical Treatment Center
-
-
Jiangsu
-
Wuxi, Jiangsu, China
- Wuxi No.5 People's Hospital
-
Xuzhou, Jiangsu, China
- The Affiliated Hospital of Xuzhou Medical University
-
-
Jilin
-
Changchun, Jilin, China, 130000
- The first hospital of JILIN University.
-
-
Nanning
-
Guangxi, Nanning, China
- The First Affiliated Hospital of Guangxi Medical University
-
-
Shanxi
-
Taiyuan, Shanxi, China
- First Hospital of Shanxi Medical University
-
-
Sichaun
-
Luzhou, Sichaun, China
- Traditional Chinese Medical Hospital Affiliated To Southwest Medical University
-
-
Sichuan
-
Chendu, Sichuan, China
- Chengdu Public Health Medical Center
-
Chengdu, Sichuan, China
- Sichuan Province General Hospital
-
-
Xinjiang
-
Ürümqi, Xinjiang, China
- First Affiliated Hospital of Xinjiang Medical University
-
Ürümqi, Xinjiang, China
- Traditional Chinese Medical Hospital Uygur Autonomous Region
-
-
Zhejiang
-
Huzhou, Zhejiang, China
- Huzhou Center Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hepatitis C virus (HCV) genotype 1 infection (confirmed at screening).
- HCVRNA greater than 10,000 IU/mL at screening.
- Participant must be willing and able to comply with the protocol requirements.
- weight was more than 40 kg.
- age is between 18-75,either sex.
Exclusion Criteria:
- Co-infection with hepatitis B virus or human immunodeficiency virus (HIV).
- Infection with HCV non-genotype 1,or Infection with mixed genotype,or Genotype cannot be confirmed.
- Medical history of major functional organ transplantation.
- Suffering from serious blood system disease(such us Thalassemia/Sickle Cell Anemia).
- Participation in a clinical study within 3 months prior to first dose
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Seraprevir and sofosbuvir
Subjects will receive oral tablets of Seraprevir 100mg twice a day along with oral tablet of sofosbuvir 400 mg,once a day from Day 1 up to Week 12.
|
Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12
Other Names:
Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Actual End of Treatment(SVR12)
Time Frame: Posttreatment Week 12
|
SVR12 is defined as HCV RNA < the lower limit of quantification (LLOQ; ie, < 15 IU/mL) 12 weeks following the last dose of study drug.
|
Posttreatment Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Achieving a Sustained Virologic Response 4 Weeks After the Actual End of Treatment (SVR4)
Time Frame: Posttreatment Week 4
|
SVR4 is defined as HCV RNA < LLOQ at 4 weeks following the last dose of study drug.
|
Posttreatment Week 4
|
|
Percentage of Participants Achieving a On-treatment Virologic Response
Time Frame: week 1,week 2,week 4,week8,week 12
|
Percentage of participants who achieved HCV RNA <LLOQ at week 1,week 2,week 4,week8,week 12.
|
week 1,week 2,week 4,week8,week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Blood-Borne Infections
- Disease Attributes
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Infections
- Communicable Diseases
- Hepatitis
- Hepatitis A
- Hepatitis C
- Virus Diseases
- Anti-Infective Agents
- Antiviral Agents
- Sofosbuvir
Other Study ID Numbers
Other Study ID Numbers
- GP205-1801
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.